Novo Nordisk: Zenagamtide and Etavopivat Shine, but the Market Only Sees CagriSema
https://www.europesays.com/dk/105248/
Novo Nordisk’s shares continue to trade under a dark cloud, down roughly 46% over the past twelve months…
Novo Nordisk’s shares continue to trade under a dark cloud, down roughly 46% over the past twelve months and hovering near €37—a far cry from the 52-week high